Premium
Recurrent Pregnancy Loss, Plasminogen Activator Inhibitor‐1 (‐675) 4G/5G Polymorphism and Antiphospholipid Antibodies in Czech Women
Author(s) -
Subrt Ivan,
UlcovaGallova Zdenka,
Cerna Monika,
Hejnalova Marketa,
Slovanova Jitka,
Bibkova Katarina,
Micanova Zdenka
Publication year - 2013
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.12099
Subject(s) - genotype , medicine , plasminogen activator , antibody , endocrinology , pregnancy , allele , plasminogen activator inhibitor 1 , immunology , biology , genetics , gene
Problem This study compares the frequencies of plasminogen activator inhibitor‐1 (‐675) 4G/5G polymorphism and its relationship with eight antiphospholipid antibodies ( aPL s) in serum of 157 patients with repeated pregnancy loss (RPL). Method of study PAI‐1 (‐675) 4G/5G polymorphism was determined using standard PCR ‐ RFLP method. Enzyme‐linked immunosorbent assay was used for the detection of aPL s against ph‐serine, ph‐ethanolamine, ph‐inositol, ph‐DL‐glycerol, phosphatidic acid, annexin V, cardiolipin, and beta2‐ GPI . Allelic frequency and distribution of genotypes were calculated. The prevalence of the risk conferring 4G allele and 4G/4G homozygous genotype in patients and controls was compared, and the correlation between aPL s positivity and PAI ‐1 4G/4G genotype was tested by chi‐square test. Results Statistically highly significant correlation between RPL and PAI ‐1 (‐675) 4G/4G genotype was found. No correlation between PAI ‐1 (‐675) 4G/5G polymorphism and the presence of antiphospholipid antibodies in RPL patients was observed. Conclusions PAI ‐1 (‐675) 4G/4G homozygous genotype increases the risk of RPL independently from the aPL s positivity.